Latest Headlines

Latest Headlines

Struggling GlobeImmune brings in financial advisers as options dwindle

Not long after after a mid-stage trial failure blasted its stock value and forced the company to lay off most of its staff, a troubled GlobeImmune has brought in Cantor Fitzgerald to advise the biotech on its "strategic options"--which may signal that a fire sale is in the offing.

Celgene buys into GlobeImmune's cancer immunotherapy

GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy.

GlobeImmune axes 'majority' of staffers in wake of trial failure

Two weeks after GlobeImmune conceded that its Gilead-partnered hepatitis B vaccine had flunked out of a key Phase II study, the Louisville, CO-based biotech said it laid off "the majority" of its staff.

GlobeImmune's Gilead-partnered hep B vaccine fails in Phase II

GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.

Add 3 more biotechs to the IPO list: Agile, Aldeyra and GlobeImmune

Three more biotechs are aiming for IPOs amid a frenzy of public offerings in the industry. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune are hoping to raise a combined $132 million.

Eager biotechs eye $133M in IPOs as a frenzied quarter closes

Three more drug developers are angling to go public in the waning days of a bustling first quarter for biotech IPOs, swinging for a combined $133 million to bankroll their programs. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune have all queued up for Wall Street debuts, hoping 2014's bull market lasts long enough to pull off offerings.

GlobeImmune pulls plug on $75M IPO despite still-bubbling market

After repeated delays, Colorado immunotherapy developer GlobeImmune has finally called it quits on plans to raise up to $74.8 million in an IPO, citing poor market conditions amid a prolonged boom in biotech debuts.

In $69M IPO bid, GlobeImmune spotlights therapeutic vaccines

GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.

GlobeImmune's $69M IPO designed to build immunotherapy pipeline

GlobeImmune is hoping to ride the new wave of enthusiasm over immunotherapies to a successful IPO designed to raise up to $69 million.

Developing proteomic signatures focus pancreatic cancer therapy

Biodesix, a Boulder, CO-based company developing diagnostics based on mass spectrometry technology, has found a proteomic signature after its analysis of a clinical trial of GlobeImmune's GI-4000 cancer vaccine in pancreatic cancer.